Goldman Sachs Group Inc Vincerx Pharma, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VINC
# of Institutions
29Shares Held
10.7MCall Options Held
0Put Options Held
0-
Prosight Management, LP Dallas, TX2.49MShares$870,9460.63% of portfolio
-
Armistice Capital, LLC New York, NY1.99MShares$695,8000.02% of portfolio
-
Sage Rhino Capital LLC1.7MShares$596,1940.34% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD892KShares$312,1010.02% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct674KShares$235,9670.0% of portfolio
About Vincerx Pharma, Inc.
- Ticker VINC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,189,800
- Market Cap $7.42M
- Description
- Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candid...